Kondo, T., Banno, H., Okunomiya, T., Amino, Y., Endo, K., Nakakura, A., Uozumi, R., Kinoshita, A., Tada, H., Morita, S., Ishikawa, H., Shindo, A., Yasuda, K., Taruno, Y., Maki, T., Suehiro, T., Mori, K., Ikeda, M., Fujita, K., Izumi, Y., Kanemaru, K., Ishii, K., Shigenobu, K., Kutoku, Y., Sunada, Y., Kawakatsu, S., Shiota, S., Watanabe, T., Uchikawa, O., Takahashi, R., Tomimoto, H., & Inoue, H. (2021). repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ open, 11(6), . http://access.bl.uk/ark:/81055/vdc_100133911172.0x00003a